--- title: "Addus HomeCare Earnings: What To Look For From ADUS" description: "Addus HomeCare is set to report earnings on Monday, with analysts expecting a 25.5% year-on-year revenue growth, up from 7.5% last year. The company previously beat revenue expectations with $362.3 mi" type: "news" locale: "en" url: "https://longbridge.com/en/news/276525138.md" published_at: "2026-02-22T03:05:20.000Z" --- # Addus HomeCare Earnings: What To Look For From ADUS > Addus HomeCare is set to report earnings on Monday, with analysts expecting a 25.5% year-on-year revenue growth, up from 7.5% last year. The company previously beat revenue expectations with $362.3 million last quarter. Despite missing estimates multiple times in the past two years, analysts have reaffirmed their forecasts. In the healthcare sector, peers have shown mixed results, with Brookdale's revenues down 3.4% and Guardant Health's up 39.4%. Addus shares are currently at $115.45, with an average analyst price target of $141. Home healthcare provider Addus HomeCare will be reporting results this Monday after the bell. Here’s what you need to know. Addus HomeCare beat analysts’ revenue expectations last quarter, reporting revenues of $362.3 million, up 25% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting Addus HomeCare’s revenue to grow 25.5% year on year, improving from the 7.5% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street’s revenue estimates multiple times over the last two years. Looking at Addus HomeCare’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Brookdale’s revenues decreased 3.4% year on year, missing analysts’ expectations by 1.7%, and Guardant Health reported revenues up 39.4%, topping estimates by 3.5%. Brookdale traded down 9.7% following the results while Guardant Health was also down 3.1%. Read our full analysis of Brookdale’s results here and Guardant Health’s results here. The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.2% on average over the last month. Addus HomeCare is up 4.6% during the same time and is heading into earnings with an average analyst price target of $141 (compared to the current share price of $115.45). ### Related Stocks - [ADUS.US - Addus Homecare](https://longbridge.com/en/quote/ADUS.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [LABD.US - Direxion S&P Biotech Bear 3X](https://longbridge.com/en/quote/LABD.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md) - [GH.US - Guardant Health](https://longbridge.com/en/quote/GH.US.md) - [IDNA.US - iShares Genomics Immunology and Healthcare ETF](https://longbridge.com/en/quote/IDNA.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 展望：Addus Homecare 的收益預測 | 愛德斯家庭護理 (NASDAQ:ADUS) 定於 2026 年 2 月 23 日發佈季度財報，分析師預測每股收益為 1.65 美元。投資者熱切期待這一公告，以獲取潛在的積極指引。上個季度，該公司超出了每股收益預期 0.10 美元，但次日股價 | [Link](https://longbridge.com/en/news/276462820.md) | | Guardant Health, Inc. $GH 的股份被 Assetmark Inc. 收購 | Assetmark Inc. 在第三季度顯著增加了對 Guardant Health, Inc. 的持股，增幅達到 18,838.6%，目前持有 13,257 股，市值為 828,000 美元。其他投資者也增加了他們的持倉。分析師們為 Gu | [Link](https://longbridge.com/en/news/276508335.md) | | Guardant Health｜8-K：2025 財年 Q4 營收 2.81 億美元超過預期 | | [Link](https://longbridge.com/en/news/276378733.md) | | Guardant Health（NASDAQ 代碼：GH）公佈季度財報結果 | Guardant Health（納斯達克代碼：GH）報告的季度每股收益為（$0.50），低於預期的（$0.43），差距為（$0.07）。收入為 2.8127 億美元，超過預期的 2.6974 億美元。該股下跌 1.0%，報 106.38 美 | [Link](https://longbridge.com/en/news/276380001.md) | | 深入解析 Insmed：16 位分析師分享他們的看法 | 在最新的季度中，16 位分析師對 Insmed（NASDAQ:INSM）給出了混合評級，平均 12 個月的目標價格為 224.19 美元，比之前的目標上漲了 0.99%。分析師們經常根據市場情況更新他們的建議，評級和目標價格也會發生顯著變化 | [Link](https://longbridge.com/en/news/276472105.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.